Further insights into coronary debulking: the EUROCARE trial of directional atherectomy and the PACT trial of pullback atherectomy.

A. Thury, G. Van Langenhove, A. J. Wardeh, D. P. Foley, P. W. Serruys

Research output: Contribution to journalArticle

Abstract

Although the principle of reducing plaque load in the coronary artery remains very appealing, clinical benefit from debulking devices has not been demonstrated unequivocally. Other approaches to prevent restenosis had been the application of various pharmacological agents. Unfortunately, the majority of clinical studies have not reproduced the promising results observed in the experimental laboratories. New frontiers in improving atherectomy devices and in optimizing concomitant medical treatment are currently being explored. We report on the EUROCARE trial investigating the possible benefit of carvedilol after coronary atherectomy, and the Pullback Atherectomy (PAC) pilot trial using a novel atherectomy device.

Original languageEnglish
Pages (from-to)185-192
Number of pages8
JournalSeminars in interventional cardiology : SIIC
Volume5
Issue number4
Publication statusPublished - Dec 2000

Fingerprint

Atherectomy
Equipment and Supplies
Coronary Atherectomy
Coronary Vessels
Pharmacology
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Further insights into coronary debulking : the EUROCARE trial of directional atherectomy and the PACT trial of pullback atherectomy. / Thury, A.; Van Langenhove, G.; Wardeh, A. J.; Foley, D. P.; Serruys, P. W.

In: Seminars in interventional cardiology : SIIC, Vol. 5, No. 4, 12.2000, p. 185-192.

Research output: Contribution to journalArticle

@article{cf2bc40e9c85447d8f58a6f460d33899,
title = "Further insights into coronary debulking: the EUROCARE trial of directional atherectomy and the PACT trial of pullback atherectomy.",
abstract = "Although the principle of reducing plaque load in the coronary artery remains very appealing, clinical benefit from debulking devices has not been demonstrated unequivocally. Other approaches to prevent restenosis had been the application of various pharmacological agents. Unfortunately, the majority of clinical studies have not reproduced the promising results observed in the experimental laboratories. New frontiers in improving atherectomy devices and in optimizing concomitant medical treatment are currently being explored. We report on the EUROCARE trial investigating the possible benefit of carvedilol after coronary atherectomy, and the Pullback Atherectomy (PAC) pilot trial using a novel atherectomy device.",
author = "A. Thury and {Van Langenhove}, G. and Wardeh, {A. J.} and Foley, {D. P.} and Serruys, {P. W.}",
year = "2000",
month = "12",
language = "English",
volume = "5",
pages = "185--192",
journal = "Seminars in interventional cardiology : SIIC",
issn = "1084-2764",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Further insights into coronary debulking

T2 - the EUROCARE trial of directional atherectomy and the PACT trial of pullback atherectomy.

AU - Thury, A.

AU - Van Langenhove, G.

AU - Wardeh, A. J.

AU - Foley, D. P.

AU - Serruys, P. W.

PY - 2000/12

Y1 - 2000/12

N2 - Although the principle of reducing plaque load in the coronary artery remains very appealing, clinical benefit from debulking devices has not been demonstrated unequivocally. Other approaches to prevent restenosis had been the application of various pharmacological agents. Unfortunately, the majority of clinical studies have not reproduced the promising results observed in the experimental laboratories. New frontiers in improving atherectomy devices and in optimizing concomitant medical treatment are currently being explored. We report on the EUROCARE trial investigating the possible benefit of carvedilol after coronary atherectomy, and the Pullback Atherectomy (PAC) pilot trial using a novel atherectomy device.

AB - Although the principle of reducing plaque load in the coronary artery remains very appealing, clinical benefit from debulking devices has not been demonstrated unequivocally. Other approaches to prevent restenosis had been the application of various pharmacological agents. Unfortunately, the majority of clinical studies have not reproduced the promising results observed in the experimental laboratories. New frontiers in improving atherectomy devices and in optimizing concomitant medical treatment are currently being explored. We report on the EUROCARE trial investigating the possible benefit of carvedilol after coronary atherectomy, and the Pullback Atherectomy (PAC) pilot trial using a novel atherectomy device.

UR - http://www.scopus.com/inward/record.url?scp=0034573778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034573778&partnerID=8YFLogxK

M3 - Article

C2 - 11244515

AN - SCOPUS:0034573778

VL - 5

SP - 185

EP - 192

JO - Seminars in interventional cardiology : SIIC

JF - Seminars in interventional cardiology : SIIC

SN - 1084-2764

IS - 4

ER -